Overview

Comparison of Efficacy of Intra-articular Morphine vs Methylprednisolone in Patients With Knee Osteoarthritis.

Status:
Withdrawn
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
Prospective randomized double-blind controlled study. Participating patients with knee pain secondary to knee osteoarthritis will be randomized to either the DepoMedrol 40mg + 0.25% Bupivacaine (total Volume 5 ml) vs Morphine 3mg group+0.5% Bupivacaine (total volume 5ml) for their intra-articular knee injection. Before the injections, baseline values of NRS (Numerical rating scale) and WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) Questionnaire will be recorded by investigator. After the injections NRS and WOMAC will be recorded at 30mins and on discharge. Patient will be contacted by phone to assess the effectivity of block or any side effects on day 1, 7,30 and 45, information including NRS (at rest and household activity), WOMAC, supplemental analgesic, Side effects (pruritus, paresthesia, urinary retention, nausea, vomiting, dizziness, rash) will be obtained from the patient at the above time intervals. follow up visit will be scheduled 60days after the procedure for re-evaluation.
Phase:
Phase 2
Details
Lead Sponsor:
Henry Ford Health System
Treatments:
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate